Cannabis has long had an image problem, because of the extremely widespread use of “narcotic” cultivars as illegal intoxicants. The US Drug Enforcement Administration has the mandate of eliminating illicit and wild marijuana, which it does very well (Fig. 54–56). Those interested in establishing and developing legitimate industries based on fiber and oilseed applications have had to struggle against considerable opposition from many in the political and law enforcement arenas. The United States National Institute on Drug Abuse (NIDA) information web site on marijuana, which reflects a negative view of cannabis, is at, and reflects several basic fears: (1) growing Cannabis plants makes law enforcement more difficult, because of the need to ensure that all plants cultivated are legitimate; (2) utilization of legitimate Cannabis products makes it much more difficult to maintain the image of the illegitimate products as dangerous; (3) many in the movements backing development of hemp are doing so as a subterfuge to promote legalization of recreational use of marijuana; and (4) THC (and perhaps other constituents) in Cannabis are so harmful that their presence in any amount in any material (food, medicine or even fiber product) represents a health hazard that is best dealt with by a total proscription.
^ Fusar-Poli, Paolo; Crippa, José A.; Bhattacharyya, Sagnik; Borgwardt, Stefan J.; Allen, Paul; Martin-Santos, Rocio; Seal, Marc; Surguladze, Simon A.; O'Carrol, Colin; Atakan, Zerrin; Zuardi, Antonio W.; McGuire, Philip K. (2009). "Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing". Archives of General Psychiatry. 66 (1): 95–105. doi:10.1001/archgenpsychiatry.2008.519. PMID 19124693.
Cannabis terpenoids also display numerous attributes that may be germane to pain treatment (McPartland and Russo 2001). Myrcene is analgesic, and such activity, in contrast to cannabinoids, is blocked by naloxone (Rao et al 1990), suggesting an opioid-like mechanism. It also blocks inflammation via PGE-2 (Lorenzetti et al 1991). The cannabis sesquiterpenoid β-caryophyllene shows increasing promise in this regard. It is anti-inflammatory comparable to phenylbutazone via PGE-1 (Basile et al 1988), but simultaneously acts as a gastric cytoprotective (Tambe et al 1996). The analgesic attributes of β-caryophyllene are increasingly credible with the discovery that it is a selective CB2 agonist (Gertsch et al 2007), with possibly broad clinical applications. α-Pinene also inhibits PGE-1 (Gil et al 1989), while linalool displays local anesthetic effects (Re et al 2000).
Medicine FinderLatest NewsVideo: New asthma guidelinesModerate alcohol consumption reduces brain functionVideo: Brain awarenessPrescribing exercise for mental healthVideo: What can be done to prevent falls?Video: Is HIIPA the new HIIT?This web site is intended for Australian residents and is not a substitute for independent professional advice. Information and interactions contained in this Web site are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further, the accuracy, currency and completeness of the information available on this Web site cannot be guaranteed. Tonic Digital Media Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through myDr whether arising from negligence or otherwise. See Privacy Policy and Disclaimer.2001-2019 © | All Rights Reserved About UsContact UsDisclaimerPrivacy PolicyAdvertising PolicySitemap
The glutamatergic system is integral to development and maintenance of neuropathic pain, and is responsible for generating secondary and tertiary hyperalgesia in migraine and fibromyalgia via NMDA mechanisms (Nicolodi et al 1998). Thus, it is important to note that cannabinoids presynaptically inhibit glutamate release (Shen et al 1996), THC produces 30%–40% reduction in NMDA responses, and THC is a neuroprotective antioxidant (Hampson et al 1998). Additionally, cannabinoids reduce hyperalgesia via inhibition of calcitonin gene-related peptide (Richardson et al 1998a). As for Substance P mechanisms, cannabinoids block capsaicin-induced hyperalgesia (Li et al 1999), and THC will do so at sub-psychoactive doses in experimental animals (Ko and Woods 1999). Among the noteworthy interactions with opiates and the endorphin/enkephalin system, THC has been shown to stimulate beta-endorphin production (Manzanares et al 1998), may allow opiate sparing in clinical application (Cichewicz et al 1999), prevents development of tolerance to and withdrawal from opiates (Cichewicz and Welch 2003), and rekindles opiate analgesia after a prior dosage has worn off (Cichewicz and McCarthy 2003). These are all promising attributes for an adjunctive agent in treatment of clinical chronic pain states.
I have idiopathic peripheral neuropathy ... the only thing they found that would work is lyrica. I picked up some CBD oil yesterday morning. I am prescribed to take 75 mg of lyrica 3x per day. I took one yesterday morning and have only used the CBD oil since. I bought the Koi brand, flavored, 250 MG. I used a full dropper yesterday late morning and a full dropper yesterday late afternoon. I used it once today (one full dropper) and I am amazingly pain free.
Executives from Canopy Growth CGC, -1.22% WEED, -1.27%  and rival Aurora Cannabis Inc. ACB, -0.88% ACB, -0.83%  both discussed their hemp operations on September-quarter earnings calls that included disappointing results related to early recreational pot sales. Aurora declined to comment on the latest developments and Canopy did not make executives available by the time of publication.
The vast majority of subjects in Sativex clinical trials do not experience psychotropic effects outside of initial dose titration intervals (Figure 2) and most often report subjective intoxication levels on visual analogue scales that are indistinguishable from placebo, in the single digits out of 100 (Wade et al 2006). Thus, it is now longer tenable to claim that psychoactive effects are a necessary prerequisite to symptom relief in the therapeutic setting with a standardized intermediate onset cannabis-based preparation. Intoxication has remained a persistent issue in Marinol usage (Calhoun et al 1998), in contrast.
Cannabidiol is insoluble in water but soluble in organic solvents such as pentane. At room temperature, it is a colorless crystalline solid.[42] In strongly basic media and the presence of air, it is oxidized to a quinone.[43] Under acidic conditions it cyclizes to THC,[44] which also occurs during pyrolysis (smoking).[45] The synthesis of cannabidiol has been accomplished by several research groups.[46][47][48]

Just as there was a shift from viewing disease as a state to thinking of it as a process, the same shift happened in definitions of health. Again, the WHO played a leading role when it fostered the development of the health promotion movement in the 1980s. This brought in a new conception of health, not as a state, but in dynamic terms of resiliency, in other words, as "a resource for living". 1984 WHO revised the definition of health defined it as "the extent to which an individual or group is able to realize aspirations and satisfy needs and to change or cope with the environment. Health is a resource for everyday life, not the objective of living; it is a positive concept, emphasizing social and personal resources, as well as physical capacities".[10] Thus, health referred to the ability to maintain homeostasis and recover from insults. Mental, intellectual, emotional and social health referred to a person's ability to handle stress, to acquire skills, to maintain relationships, all of which form resources for resiliency and independent living.[9] This opens up many possibilities for health to be taught, strengthened and learned.

THC and its major (inactive) metabolite, THC-COOH, can be measured in blood, urine, hair, oral fluid or sweat using chromatographic techniques as part of a drug use testing program or a forensic investigation of a traffic or other criminal offense.[53] The concentrations obtained from such analyses can often be helpful in distinguishing active use from passive exposure, elapsed time since use, and extent or duration of use. These tests cannot, however, distinguish authorized cannabis smoking for medical purposes from unauthorized recreational smoking.[150] Commercial cannabinoid immunoassays, often employed as the initial screening method when testing physiological specimens for marijuana presence, have different degrees of cross-reactivity with THC and its metabolites.[151] Urine contains predominantly THC-COOH, while hair, oral fluid and sweat contain primarily THC.[53] Blood may contain both substances, with the relative amounts dependent on the recency and extent of usage.[53]

According to the United Nations Office on Drugs and Crime (UNODC), "the amount of THC present in a cannabis sample is generally used as a measure of cannabis potency."[159] The three main forms of cannabis products are the flower, resin (hashish), and oil (hash oil). The UNODC states that cannabis often contains 5% THC content, resin "can contain up to 20% THC content", and that "Cannabis oil may contain more than 60% THC content."[159]
Generally, the context in which an individual lives is of great importance for both his health status and quality of their life It is increasingly recognized that health is maintained and improved not only through the advancement and application of health science, but also through the efforts and intelligent lifestyle choices of the individual and society. According to the World Health Organization, the main determinants of health include the social and economic environment, the physical environment and the person's individual characteristics and behaviors.[18]
Cannabis use and psychotic symptoms and disorders are associated in the general population (see, for example, Degenhardt and Hall, 2001; Tien and Anthony, 1990) and in clinical samples of patients with schizophrenia (Mueser et al., 1992; Warner et al., 1994; Hambrecht and Hafner, 1996). The major contending hypotheses to explain the association have been: (i) that cannabis use precipitates schizophrenia in persons who are otherwise vulnerable; (ii) cannabis use is a form of self-medication for schizophrenia; and (iii) that the association arises from uncontrolled residual confounding by variables that predict an increased risk of cannabis use and of schizophrenia (Macleod et al., 2004).
In 1925, a compromise was made at an international conference in The Hague about the International Opium Convention that banned exportation of "Indian hemp" to countries that had prohibited its use, and requiring importing countries to issue certificates approving the importation and stating that the shipment was required "exclusively for medical or scientific purposes". It also required parties to "exercise an effective control of such a nature as to prevent the illicit international traffic in Indian hemp and especially in the resin".[211][212] In the United States in 1937, the Marihuana Tax Act was passed,[213] and prohibited the production of hemp in addition to cannabis.